These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9803250)

  • 1. Should we be screening blood donors for hepatitis G virus? The case for screening.
    Moaven LD
    Med J Aust; 1998 Oct; 169(7):373-4. PubMed ID: 9803250
    [No Abstract]   [Full Text] [Related]  

  • 2. Should we be screening blood donors for hepatitis G virus? The case against screening.
    Wong PY; Coghlan PJ; Angus PW
    Med J Aust; 1998 Oct; 169(7):375-7. PubMed ID: 9803251
    [No Abstract]   [Full Text] [Related]  

  • 3. Antibodies to the E2 protein of hepatitis G virus in blood donors in New Zealand.
    Woodfield G; Roberts M
    N Z Med J; 1998 Nov; 111(1078):459-60. PubMed ID: 9891569
    [No Abstract]   [Full Text] [Related]  

  • 4. Proper donor screening--a good prevention of transfusion transmitted AIDS and hepatitis.
    Chatterjee K
    J Acad Hosp Adm; 1994 Jul; 6(2):49-52. PubMed ID: 10537998
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevalence, persistence and liver enzyme levels of HGV RNA-positive blood donors determined by large-scale screening and transmission by blood components.
    Hitzler WE; Runkel S
    Clin Lab; 2004; 50(1-2):25-31. PubMed ID: 15000218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of hepatitis GB virus C/hepatitis G virus infection in blood donors in India.
    Thakur V; Guptan RC; Sarin SK
    J Assoc Physicians India; 2000 Aug; 48(8):818-9. PubMed ID: 11273477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and screening costs of hepatitis C virus among Ugandan blood donors.
    Hladik W; Kataaha P; Mermin J; Purdy M; Otekat G; Lackritz E; Alter MJ; Downing R
    Trop Med Int Health; 2006 Jun; 11(6):951-4. PubMed ID: 16772018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
    Busch MP
    Transfus Clin Biol; 2004 Feb; 11(1):26-32. PubMed ID: 14980546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevalence of hepatitis G virus among Tunisian blood donors].
    Mastouri M; Safer IL; Pozzetto B; Bourlet T; Khedher M
    East Mediterr Health J; 2005; 11(5-6):1053-60. PubMed ID: 16761677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis G virus infection in hemodialysis patients: fact or fancy?
    Macedo G; Pereira O; Carvalho B; Loureiro A
    Am J Gastroenterol; 1999 May; 94(5):1423-4. PubMed ID: 10235242
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hepatitis G virus exists--but does hepatitis G?].
    Wejstål R; Lindberg J
    Lakartidningen; 1999 Jan; 96(4):323-6. PubMed ID: 10024820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hepatitis alphabet--hepatitis A-G and TTV.
    Müller C
    Wien Klin Wochenschr; 1999 Jun; 111(12):461-8. PubMed ID: 10420504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [GPT limit values in blood donors: lower, higher or eliminate completely?].
    Caspari G; Gerlich WH
    Infusionsther Transfusionsmed; 1995 Jun; 22(3):142-4. PubMed ID: 7640508
    [No Abstract]   [Full Text] [Related]  

  • 14. [GB virus-C/hepatitis G virus--discovery, epidemiology, diagnosis and clinical relevance].
    Sarrazin C; Roth WK; Zeuzem S
    Z Gastroenterol; 1998 Nov; 36(11):997-1008. PubMed ID: 9880826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening blood donors for HTLV-1: a case for a cost-benefit analysis.
    West Indian Med J; 1990 Sep; 39(3):195-6. PubMed ID: 2124755
    [No Abstract]   [Full Text] [Related]  

  • 16. [Eliminating alanine aminotransferase (ALT) determination in screening of blood components for transfusion and plasma for fractionation. At the 52nd Meeting of the Blood Professional Circle 1 October 2003 the following vote (V30) was delivered].
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2004 Jan; 47(1):82. PubMed ID: 15205830
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevalence of TT virus infection in blood donors with elevated ALT in the absence of known hepatitis markers.
    Cleavinger PJ; Persing DH; Li H; Moore SB; Charlton MR; Sievers C; Therneau TM; Zein NN
    Am J Gastroenterol; 2000 Mar; 95(3):772-6. PubMed ID: 10710073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of hepatitis G virus (HGV) RNA, antibody to HGV envelope protein, and risk factors for blood donors coinfected with HGV and hepatitis C virus.
    Tan D; Matsumoto A; Conry-Cantilena C; Melpolder JC; Shih JW; Leuther M; Hess G; Gibble JW; Ness PM; Alter HJ
    J Infect Dis; 1999 May; 179(5):1055-61. PubMed ID: 10191204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus.
    Seed CR; Kiely P; Keller AJ
    Intern Med J; 2005 Oct; 35(10):592-8. PubMed ID: 16207258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum pooling for screening of blood donors for hepatitis C virus antibody.
    Kini S; Kumar S; Sharma RR; Thakral B; Agnihotri SK
    Indian J Pathol Microbiol; 2003 Jul; 46(3):537-8. PubMed ID: 15025337
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.